O
OrbiMed Portfolio holdings
AUM
$5.4B
Turnover
40.13%
1-Year Est. Return
163.13%
This Fund
S&P 500
This Quarter
Est. Return
-4.57%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$9.89B
AUM Growth
-$808M
(-7.6%)
Cap. Flow
+$275M
Cap. Flow
% of AUM
2.78%
Top 10 Holdings %
Top 10 Hldgs %
30.49%
Holding
183
New
24
Increased
25
Reduced
25
Closed
24
Avg Time Held Equity + Options
1.7
years
Top 10 Avg Time Held Equity + Options
0.5
years
Top 20 Avg Time Held Equity + Options
1.6
years
Avg Time Held Equity only
1.7
years
Top 10 Avg Time Held Equity only
0.5
years
Top 20 Avg Time Held Equity only
1.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P Biotech ETF
XBI
|
+$123M |
| 2 |
Neuropace
NPCE
|
+$93.1M |
| 3 |
VECT
VectivBio Holding AG Ordinary Shares
VECT
|
+$77.8M |
| 4 |
Janux Therapeutics
JANX
|
+$77.2M |
| 5 |
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
+$74.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Haemonetics
HAE
|
+$94.6M |
| 2 |
AbCellera Biologics
ABCL
|
+$54.5M |
| 3 |
Adverum Biotechnologies
ADVM
|
+$54.2M |
| 4 |
Molina Healthcare
MOH
|
+$38M |
| 5 |
PAND
Pandion Therapeutics Inc. Common Stock
PAND
|
+$31.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.72% |
| 2 | Miscellaneous | 4.15% |
| 3 | Technology | 0.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
Cullinan Oncology
CGEM
$878M
| $29.5M | 0.3% |
1,146,145
| – | – |
2021 Q1
1 quarter
|
|
77
DELISTED
scPharmaceuticals
SCPH
| $29.3M | 0.3% |
4,797,148
| – | – |
2017 Q4
14 quarters
|
|
78
KALA BIO
KALA
$3.64M
| $29M | 0.29% |
2,188
| – | – |
2017 Q3
15 quarters
|
|
|
SRRA
79
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $28.8M | 0.29% |
1,477,320
| – | – |
2020 Q1
5 quarters
|
|
80
Standard BioTools
LAB
$248M
| $28.7M | 0.29% |
4,661,871
+62,300
| +1% | +$333K |
2020 Q2
4 quarters
|
|
81
Arcturus Therapeutics
ARCT
$316M
| $28.7M | 0.29% |
848,503
-358,383
| -30% | -$12.1M |
2020 Q2
4 quarters
|
|
82
Curis
CRIS
$1.45M
| $28.4M | 0.29% |
8,804
-2,112
| -19% | -$9.54M |
2019 Q3
7 quarters
|
|
83
Spyre Therapeutics
SYRE
$7.35B
| $27.9M | 0.28% |
160,621
| – | – |
2016 Q2
20 quarters
|
|
|
ALXN
84
DELISTED
Alexion Pharmaceuticals
ALXN
| $27.7M | 0.28% |
150,900
+48,800
| +48% | +$8.38M |
2013 Q2
32 quarters
|
|
85
DELISTED
Alpine Immune Sciences Inc
ALPN
| $27.6M | 0.28% |
3,070,955
| – | – |
2017 Q3
15 quarters
|
|
|
APTO
86
DELISTED
Aptose Biosciences, Inc.
APTO
| $26.7M | 0.27% |
17,844
| – | – |
2019 Q4
6 quarters
|
|
87
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $26.1M | 0.26% |
3,224,770
| – | – |
2020 Q2
4 quarters
|
|
88
Xenon Pharmaceuticals
XENE
$3.28B
| $24.8M | 0.25% |
1,334,217
-1,163,700
| -47% | -$21.5M |
2016 Q3
19 quarters
|
|
89
Biogen
BIIB
$34.4B
| $23.3M | 0.24% |
67,400
-14,600
| -18% | -$4.42M |
2013 Q2
32 quarters
|
|
90
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $22.8M | 0.23% |
2,769,383
+461,300
| +20% | +$3.92M |
2019 Q4
6 quarters
|
|
91
CalciMedica
CALC
$7.31M
| $22.6M | 0.23% |
59,476
| – | – |
2020 Q3
3 quarters
|
|
92
Olema Pharmaceuticals
OLMA
$595M
| $22.6M | 0.23% |
807,792
+151,666
| +23% | +$4.32M |
2020 Q4
2 quarters
|
|
93
NextCure
NXTC
$30.1M
| $21.8M | 0.22% |
225,918
| – | – |
2019 Q2
8 quarters
|
|
94
Corvus Pharmaceuticals
CRVS
$789M
| $21.5M | 0.22% |
8,053,298
| – | – |
2016 Q1
21 quarters
|
|
95
Enliven Therapeutics
ELVN
$2.88B
| $21.5M | 0.22% |
679,976
| – | – |
2020 Q1
5 quarters
|
|
96
Vaxcyte
PCVX
$10.6B
| $21.3M | 0.22% |
945,400
+296,626
| +46% | +$6.07M |
2020 Q2
4 quarters
|
|
|
DMRA
97
Damora Therapeutics
DMRA
$1.14B
| $20.7M | 0.21% |
163,637
| – | – |
2020 Q4
2 quarters
|
|
98
Dianthus Therapeutics
DNTH
$4.18B
| $19.9M | 0.2% |
127,110
+67,794
| +114% | +$12.5M |
2021 Q1
1 quarter
|
|
99
Gilead Sciences
GILD
$190B
| $19.8M | 0.2% |
287,600
| – | – |
2013 Q2
32 quarters
|
|
|
KDNY
100
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $18.8M | 0.19% |
1,333,801
+83,800
| +7% | +$1.34M |
2020 Q4
2 quarters
|
|
Similar funds
MYIA
SCM
BJL
BG
SNT
NL
RC
AC
OrbiMed's Q2 2021 Portfolio in Review
As of Q2 2021, OrbiMed held 183 positions worth $9.89B, down 7.6% from $10.7B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
OrbiMed's Q2 2021 filing shows 24 new, 25 increased, 25 reduced and 24 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 935,700 shares worth $127M. The largest sale was Haemonetics, an estimated $94.6M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Miscellaneous and Technology.
- OrbiMed's largest Q2 2021 buy was State Street SPDR S&P Biotech ETF: 935,700 shares worth $127M.
- OrbiMed added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2021, an estimated $74.2M increase.
- OrbiMed's biggest Q2 2021 reduction was AbCellera Biologics, cutting an estimated $54.5M.
- OrbiMed fully exited Haemonetics in Q2 2021, selling an estimated $94.6M.
- OrbiMed's ten largest holdings make up 30% of its $9.89B portfolio in Q2 2021.
- OrbiMed opened 24 new positions and closed 24 in Q2 2021.
- OrbiMed's portfolio value fell 7.6% quarter-over-quarter to $9.89B.
Based on OrbiMed's 13F filing for Q2 2021, filed 16 Aug 2021.